Compare SII & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SII | PGEN |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | 2011 | 2013 |
| Metric | SII | PGEN |
|---|---|---|
| Price | $107.46 | $4.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $132.07 | $14.00 |
| AVG Volume (30 Days) | 101.1K | ★ 7.3M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.58% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $42.44 | $2,335.22 |
| Revenue Next Year | N/A | $85.34 |
| P/E Ratio | $63.42 | ★ $38.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $80.53 | $3.04 |
| 52 Week High | $169.63 | $8.98 |
| Indicator | SII | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 42.49 | 35.21 |
| Support Level | $101.76 | $3.65 |
| Resistance Level | $109.99 | $5.75 |
| Average True Range (ATR) | 4.00 | 0.47 |
| MACD | 0.70 | -0.07 |
| Stochastic Oscillator | 41.61 | 21.58 |
Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.